A
5.06
2.20 (77.16%)
| Previous Close | 2.86 |
| Volume | 15,390,751 |
| Price / Sales | 75.34 |
| Price / Book | 1.30 |
| 52 Weeks Range |
| Profit Margin | 3,521.74% |
| Operating Margin (TTM) | -853.23% |
| Diluted EPS (TTM) | -7.46 |
| Quarterly Revenue Growth (YOY) | -69.80% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 3.03 |
| Operating Cash Flow (TTM) | -3.78 M |
| Levered Free Cash Flow (TTM) | -3.57 M |
| Return on Assets (TTM) | -25.09% |
| Return on Equity (TTM) | -163.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Addex Therapeutics Ltd | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ADXN | - | - | - | 1.30 |
| SONN | 33 M | - | - | 2.07 |
| CDIO | - | - | - | 0.740 |
| REPL | - | - | - | 10.78 |
| INDP | - | - | - | 33.86 |
| IFRX | - | - | - | 1.09 |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | 1.2 |
| AI Technical info | NA |
| Technical Oscillators info | 2.0 |
| Technical Moving Averages info | 0.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.4% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -0.5 |
| Final Score | 0.33 |
Select this tab to load the latest available analysis.
|
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Institutions | 1.13% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
Addex Spin-out Neurosterix Closes $105 Million Series B Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that… |
| 29 Oct 2026 | Yahoo Finance |
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today… |
| 08 Oct 2026 | Yahoo Finance |
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced… |
| 02 Oct 2026 | Yahoo Finance |
Addex Therapeutics Announces Executive Management Changes
Jean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company… |
| 28 Sep 2026 | Yahoo Finance |
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its… |
| 28 Sep 2026 | Yahoo Finance |
Addex (ADXN) Q2 2026 Earnings Call Transcript
Biotech regains GABAB rights, extends cash runway into Q4 2027… |
| 25 Sep 2026 | Yahoo Finance |
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained… |
| 24 Sep 2026 | Yahoo Finance |
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and… |
| 26 Aug 2026 | Yahoo Finance |
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it… |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |